N/A
N=30
Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions
Pigmented Skin Lesion
Bottom Line
View on ClinicalTrials.gov: NCT04202419 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcome: Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- FRAX 1940 nm laser (Device)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Candela Corporation
- Primary completion
- Apr 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pigmented Lesion Improvement by Blinded Evaluation |
41 | — |
| SECONDARY Pigmentation Improvement at the 3-month Follow-up, by Blinded Evaluation |
35 | — |
| SECONDARY Blinded Assessment of Textural Improvement Using a 5-point Global Aesthetic Improvement Scale (GAIS) |
1; 16; 28 | — |
| SECONDARY Subject Assessment of Improvement Using a 5-point Global, Aesthetic Improvement Scale (GAIS) |
1; 3; 17; 10; 14 | — |
| SECONDARY Subject Satisfaction With Treatment Results |
1; 2; 14; 12; 15 | — |
Summary
This study is being conducted to evaluate the safety and efficacy of a fractional diode laser for treatment of pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sunspots), and ephelides (freckles).
Eligibility Criteria
Inclusion Criteria
- Male or Female
- Age 21 to 70
- Fitzpatrick Skin Type I to VI
- Willingness to have test spots and up to three (3) treatments for pigmented lesions on or off the face which are rated at baseline as moderate or higher per Investigator or study staff
- Provide signed informed consent to participate in the study
- Adhere to study treatment and follow-up schedules
- Willing to have hair removed from the intended treatment area prior to treatment and/or photography
- Avoid sun exposure to all treated areas and use of sunscreen with sun protection factor (SPF) 30 or greater throughout the duration of the study
- Adhere to post-treatment care instructions
- Allow photography of treated areas and to release their use for scientific and/or promotional purposes
Exclusion Criteria
- Pregnant, planning to become pregnant, or breast feeding during the study
- Allergy to lidocaine or similar medications
- Excessively tanned skin in the intended treatment area
- Open wound or infection in the intended treatment area
- Tattoo(s) or permanent make-up in the intended treatment area
- Skin condition in the intended treatment area that could interfere with treatment or evaluation of safety or efficacy
- Presence or history of melasma
- Presence or history of skin cancer within the treatment area
- History of keloid or hypertrophic scar formation
- History of herpes simplex virus (HSV) or similar condition in the intended treatment area unless treated with prophylactic medication
- Diagnosed coagulation disorder
- Immunosuppression disorder
- Presence of any medical condition that in the opinion of the Investigator could impair healing or outcome as a result of treatment
- Use of systemic retinoid therapy (e.g. Accutane) during the past six (6) months
- Use of topical retinoid therapy in the intended treatment area during the past two (2) weeks
- Use of oral corticosteroid therapy during the past four (4) weeks
- Prior treatment, such as surgery, light, laser or radiofrequency (RF) procedures in the intended treatment area during the past three (3) months
- Prior injectable dermal fillers (e.g. collagen, hyaluronic acid) in the intended treatment area within the past 12 months
- Prior injectable toxins (e.g. Botox) in the intended treatment area within the past three (3) months
- Subjects who in the opinion of the Investigator are unwilling or unable to adhere to the study requirements, or who are otherwise not a good candidate for the study
Data sourced from ClinicalTrials.gov (NCT04202419). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.